Author name: Emily Collins, Nutrition Researcher (Supplements & Superfoods)

If you have seen Epitalon sold online as a "telomere peptide" that extends human lifespan, the reasonable question to ask is: where did that claim actually come from, and has any independent group confirmed it? The honest answer is that every piece of compelling human evidence for Epitalon comes from a single Russian research group […]

You have probably seen Semax described in nootropic forums as a compound Russian cosmonauts supposedly used to stay sharp in orbit, or as a neuroprotective agent approved by a government that understood brain science before the West caught up. The origin story is partly true — Semax really was developed in the Soviet Union, really

You have probably seen Selank described in nootropic forums as the Russian government's answer to anxiety — an approved drug that sidesteps benzodiazepine dependence while also improving cognition. That narrative is compelling enough that it drives a meaningful grey-market trade in vials of unknown purity shipped from unregulated suppliers. The obvious follow-up question is whether

If you have severe osteoporosis, you have probably heard that most bone drugs work by slowing breakdown rather than building new bone. That framing is mostly accurate, and it is exactly why teriparatide gets attention: it works in the other direction. But is it for everyone with low bone density? Almost certainly not. And is

Synthetic oxytocin is the same nine-amino-acid molecule whether it arrives in an IV bag hanging above a labor-and-delivery bed or in a small amber bottle mailed from a compounding pharmacy. The FDA-approved version, sold under the brand name Pitocin, has been used in hospital obstetric wards since the 1960s, backed by decades of clinical data

You may have come across octreotide in a bodybuilding forum or a wellness thread with the vague framing that it "blocks GH" or helps with "spot reduction." That framing is worth pausing on, because octreotide is a serious prescription drug with a specific set of FDA-approved indications, a well-documented side-effect profile, and zero clinical evidence

Tesamorelin has one thing no other GHRH analog peptide can claim: an FDA approval. That approval is real, the Phase 3 trial data behind it are solid, and the mechanism is well understood. But the indication is narrow — HIV-associated lipodystrophy, specifically the excess visceral fat that accumulates in people on long-term antiretroviral therapy —